202 related articles for article (PubMed ID: 29515281)
1. Fatal dapsone hypersensitivity syndrome with hypothyroidism and steroid-induced diabetes mellitus.
Pai S; Munshi R; Nayak C
Indian J Pharmacol; 2017; 49(5):396-398. PubMed ID: 29515281
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy.
Liu H; Wang Z; Bao F; Wang C; Sun L; Zhang H; Yu G; Mi Z; Li J; Li L; Zhao Q; Yue Z; Zhao W; Yu W; Cao J; Xiong F; Wang Y; Chai Z; Cheng X; Zhang Y; Fu F; Lang X; Wang X; Irwanto A; Krismawati H; Fu X; Sun Y; You J; Liu J; Pan Q; Chu T; Liu D; Chen S; Shen J; Yan L; Zhang G; Liu J; Zhang F; ; Xiong L; Yang J; Li J; Ke W; Li M; Ning Y; Xiong J; Li M; Xiong M; Yang B; Duan Q; Wang H; Li W; Kuang Y; Li J; Wang L; Cao Q; Xiao P; Xiao B; Zhang L; Lin Z; Wang Y; Shen Y; Yan L; Wu W; Zheng H; Zhan X; Li W; Shang X; Xu Y; Liu Q
JAMA Dermatol; 2019 Jun; 155(6):666-672. PubMed ID: 30916737
[TBL] [Abstract][Full Text] [Related]
3. Mortality due to dapsone hypersensitivity syndrome complicating multi-drug therapy for leprosy in Nepal.
Pandey B; Shrestha K; Lewis J; Hawksworth RA; Walker SL
Trop Doct; 2007 Jul; 37(3):162-3. PubMed ID: 17716505
[TBL] [Abstract][Full Text] [Related]
4. Dapsone: An Update.
Karjigi S; Murthy SC; Kallappa H; Kusuma MR; Aruna B; Reddy YN
Indian J Lepr; 2016 Sep; 87(4):233-239. PubMed ID: 29762952
[TBL] [Abstract][Full Text] [Related]
5. Dapsone hypersensitivity syndrome in a lepromatous leprosy patient--A Case Report.
Gavilanes MC; Palacio AL; Chellini PR; Nery JA; Rego JG
Lepr Rev; 2015 Jun; 86(2):186-90. PubMed ID: 26502691
[TBL] [Abstract][Full Text] [Related]
6. A lethal case of the dapsone hypersensitivity syndrome involving the myocardium.
Hoogeveen RM; van der Bom T; de Boer HH; Thurlings RM; Wind BS; de Vries HJ; van Lent AU; Beuers U; van der Wal AC; Nellen FJ
Neth J Med; 2016 Feb; 74(2):89-92. PubMed ID: 26951355
[TBL] [Abstract][Full Text] [Related]
7. Dapsone hypersensitivity syndrome in non-leprosy patients: a retrospective study of its incidence in a tertiary referral center in Taiwan.
Sheen YS; Chu CY; Wang SH; Tsai TF
J Dermatolog Treat; 2009; 20(6):340-3. PubMed ID: 19954390
[TBL] [Abstract][Full Text] [Related]
8. Dapsone syndrome with acute renal failure during leprosy treatment: case report.
Alves-Rodrigues EN; Ribeiro LC; Silva MD; Takiuchi A; Fontes CJ
Braz J Infect Dis; 2005 Feb; 9(1):84-6. PubMed ID: 15947852
[TBL] [Abstract][Full Text] [Related]
9. Increase in the incidence of dapsone hypersensitivity syndrome--an appraisal.
Rao PN; Lakshmi TS
Lepr Rev; 2001 Mar; 72(1):57-62. PubMed ID: 11355519
[TBL] [Abstract][Full Text] [Related]
10. A Review on Dapsone Hypersensitivity Syndrome Among Chinese Patients with an Emphasis on Preventing Adverse Drug Reactions with Genetic Testing.
Wang N; Parimi L; Liu H; Zhang F
Am J Trop Med Hyg; 2017 May; 96(5):1014-1018. PubMed ID: 28167593
[TBL] [Abstract][Full Text] [Related]
11. Validation study of HLA-B*13:01 as a biomarker of dapsone hypersensitivity syndrome in leprosy patients in Indonesia.
Krismawati H; Irwanto A; Pongtiku A; Irwan ID; Maladan Y; Sitanggang YA; Wahyuni T; Tanjung R; Sun Y; Liu H; Zhang F; Oktavian A; Liu J
PLoS Negl Trop Dis; 2020 Oct; 14(10):e0008746. PubMed ID: 33064728
[TBL] [Abstract][Full Text] [Related]
12. Case Report: A Case of Type 1 Leprosy Reaction and Dapsone Hypersensitivity Syndrome Complicating the Clinical Course of Multibacillary Leprosy.
Craig J; MacRae C; Melvin RG; Boggild AK
Am J Trop Med Hyg; 2019 May; 100(5):1145-1148. PubMed ID: 30915953
[TBL] [Abstract][Full Text] [Related]
13. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
Sapkota BR; Shrestha K; Pandey B; Walker SL
Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
[TBL] [Abstract][Full Text] [Related]
14. Dapsone hypersensitivity syndrome in an adolescent during treatment during of leprosy.
Bucaretchi F; Vicente DC; Pereira RM; Tresoldi AT
Rev Inst Med Trop Sao Paulo; 2004; 46(6):331-4. PubMed ID: 15654479
[TBL] [Abstract][Full Text] [Related]
15. Th17 Response of Borderline-Lepromatous Leprosy Inhibits Rash Manifestation of Dapsone Hypersensitivity Syndrome: Case Report.
de Nardo Vanzela T; Bernardes Filho F; Wambier CG; Faria FM; Foss NT; Frade MAC
Am J Dermatopathol; 2018 Mar; 40(3):205-208. PubMed ID: 28937434
[TBL] [Abstract][Full Text] [Related]
16. Dapsone hypersensitivity syndrome among leprosy patients in China.
Tian W; Shen J; Zhou M; Yan L; Zhang G
Lepr Rev; 2012 Dec; 83(4):370-7. PubMed ID: 23614255
[TBL] [Abstract][Full Text] [Related]
17. A docking model of dapsone bound to HLA-B*13:01 explains the risk of dapsone hypersensitivity syndrome.
Watanabe H; Watanabe Y; Tashiro Y; Mushiroda T; Ozeki T; Hashizume H; Sueki H; Yamamoto T; Utsunomiya-Tate N; Gouda H; Kusakabe Y
J Dermatol Sci; 2017 Dec; 88(3):320-329. PubMed ID: 28870516
[TBL] [Abstract][Full Text] [Related]
18. The HLA-B*13:01 and the dapsone hypersensitivity syndrome in Korean and Asian populations: genotype- and meta-analyses.
Park HJ; Park JW; Kim SH; Choi SY; Kim HK; Jung CG; Yang MS; Kang DY; Cho MK; Kwon HS; Kang HR; Lee YW;
Expert Opin Drug Saf; 2020 Oct; 19(10):1349-1356. PubMed ID: 32700588
[TBL] [Abstract][Full Text] [Related]
19. The Function of HLA-B*13:01 Involved in the Pathomechanism of Dapsone-Induced Severe Cutaneous Adverse Reactions.
Chen WT; Wang CW; Lu CW; Chen CB; Lee HE; Hung SI; Choon SE; Yang CH; Liu MT; Chen TJ; Fan WL; Su SC; Lin YY; Chang YC; Chung WH;
J Invest Dermatol; 2018 Jul; 138(7):1546-1554. PubMed ID: 29458119
[TBL] [Abstract][Full Text] [Related]
20. Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy.
Deps P; Guerra P; Nasser S; Simon M
Lepr Rev; 2012 Sep; 83(3):305-7. PubMed ID: 23356031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
